This study examines a new drug, **KN510713**, combined with **mFOLFIRINOX**, a chemotherapy treatment for advanced pancreatic cancer. The study has two parts: finding the right dose and expanding to more people. Participants need to be 19 to 75 years old, have a confirmed diagnosis of advanced pancreatic cancer, and must be able to start mFOLFIRINOX treatment. Some medical conditions, previous treatments, or certain medications may disqualify you from participating. The study aims to see if the new drug is safe and effective.
- Duration: The study involves ongoing participation with regular check-ups.
- Visits: Participants will need to visit the study center for treatments and monitoring.
- Risks: There may be side effects from the new drug and chemotherapy.